HG Semiconductor Announces Key Management Appointments ACN Newswire

HG Semiconductor Announces Key Management Appointments

HONG KONG, Feb 7, 2023 - (ACN Newswire via SEAPRWire.com) - HG Semiconductor Limited ("HG Semiconductor", together with its subsidiaries, "the Group"; stock code: 6908. HK) today announced the appointments of Dr. XU Zhihong ("Dr. Xu") as Vice Chairman and Executive Director; Dr. CAO Yu ("Dr. Cao") as Chief Executive Officer and Executive Director; and Dr. CHEN Zhen ("Dr. Chen") as Executive Director, with effect from 6 February 2023. The appointments are expected to further strengthen the Group's third-generation semiconductor business. Dr. Xu, previously the managing director of CMB Wing Lung Bank Limited and general manager of the Financial Markets Department of Industrial and Commercial Bank of China, has extensive experience in corporate financial planning. He has received the honour of Special Government Allowances of the State Council as a National Expert, and also served as a committee member of the Financial Products Committee of the People's Bank of China and a council member of the China Urban Financial Society. Dr. Xu held senior management position of China Dive Company Limited (stock code: 300526.SZ) and DTXS Silk Road Investment Holdings Company Limited (stock code: 0620.HK). Dr. Cao has joined HG Semiconductor since 2021, and is the Vice President of Engineering of Xuzhou GSR Semiconductor Co., Ltd. ("Xuzhou GSR") and FastPower Inc. ("FastPower") which are respectively the indirect subsidiary and wholly-owned subsidiary of the Group. Dr. Cao is a core expert in the compound semiconductor business with over 20 years of proven semiconductor research, development and production experience in epitaxial growth, characterisation, device design and processing of electronic and optoelectronic devices based on GaN, InN, AlN, GaAs, InP, and related ternary and quaternary alloys. Dr. Cao has authored/co-authored 4 book/book chapters, 12 filed patents, and over 170 journal and conference papers. As a Senior Member of the Institute of Electrical and Electronics Engineers ("IEEE"), he has also served as a committee member for IEEE EDS Compound Semiconductor Devices & Circuits Committee (2019-present) and IEEE Senior Member Application Review Panel (2021-present), as well as Electrochemical Society ("ECS") Member at large, Electronics and Photonics Division: EPD executive committee member (2021-present). Dr. Cao was a technical committee member and session chair for Device Research Conference (2016-2018), International Workshop on Nitride Semiconductors (2018), Lester Eastman Conference (2018, 2020, 2021), IEEE Electron Devices Technology and Manufacturing (2021, 2022), ECS Meetings (2019-2021). He received IEEE George E. Smith Award in 2016 and is an invited reviewer for 15 prestigious research journals.Dr. Chen, joined the Group in 2021 and is a core expert in the GaN semiconductor business and the general manager of Xuzhou GSR. He is also a director of FastPower, with over 20 years of experience in research, development, production and management in the field of GaN-based optoelectronics devices. He has mastered the core technologies of GaN electronic devices and fullband solid-state light-emitting devices as well as proprietary technology of 8-inch silicon-based GaN epitaxial growth. He had been a Research Fellow with Singapore-MIT Alliance, a Postdoctoral Fellow with the University of South Carolina, and an Associate Project Scientist with University of California at Santa Barbara, where he had also worked with Nobel Prize winner Professor Shuji Nakamura and Professor Umesh Mishra, a member of the American Academy of Engineering, in relation to the performance of GaN high electron mobility transistor developed by the University of California, and researched GaN based ultraviolet to visible LED design, growth and characterization, applications in high-power, high frequency electronics. Dr. Chen also held a core management and technical position in Nanchang Lattice Power Corporation where he was involved in the production of silicon-based GaN whereby the company won the first prize of China's National Science and Technology Innovation Award in 2015.Dr. Chen has been the vice president of a well-known semiconductor company in the United States, where he is engaged in the research, development and production of GaN-based external devices. He has authored or coauthored 3 book chapters, over 50 peer reviewed papers and 20 conference proceedings. He has applied for more than 30 domestic and foreign patents and more than 10 patents have been granted. Dr. Chen is also a senior member of the IEEE Photonics Society, and a senior member of the IEEE Electronic Devices Association. His current research interests include III-nitride-based electronic devices and optical devices with wavelength from red to deep ultraviolet. Pursuant to the service agreements between the Group and Dr. Xu, Dr. Cao and Dr. Chen respectively, Dr. Xu, Dr. Cao and Dr. Chen have been appointed as Executive Directors of the Group for an initial term of three years commencing from 6 February 2023, renewable automatically for successive terms of one year each commencing from the next day after the expiry of the then term of employment, subject to retirement by rotation and re-election at annual general meetings in accordance with the articles of association of the Group and the Listing Rules.The management of HG Semiconductor welcome Dr. Xu, Dr. Cao and Dr. Chen for joining the Board. Leveraging the extensive experiences and expertise of the three leaders, the Group believes this will facilitate the development of its third-generation semiconductor GaN business and accelerate the achievement of its goal to become an integrated device manufacturing ("IDM") enterprise, further leading the Group to the path of success. Meanwhile, at the second group study session held by the Political Bureau of the Communist Party of China (CPC) Central Committee, President Xi Jinping stressed that it is imperative to accelerate self-reliance in science and technology so as to relieve the shackles imposed by some countries whom have tightened on China's development of core technologies. To echo with the national policy, the Hong Kong Innovation & Technology (I&T) Development Blueprint promulgated by the Hong Kong Government clearly pointed out that the government will strengthen the support for strategic industries, including new energy vehicles and semiconductor chips. Thus, the management of the Group believes that growing opportunities will be presented under the national and local governments' support. Following the appointment of the industry experts, it is expected that the Group will embark on a new phase of high-growth. The Group will continue its efforts to pursue its business expansion, with an ultimate goal of achieving long-term sustainable growth and brining the best returns to its shareholders.About HG Semiconductor LimitedHG Semiconductor Limited (6908.HK) is principally engaged in semiconductor product business in China, including the design, development, manufacturing, subcontracting services and sales of light-emitting diode ("LED") beads and a new generation of semiconductor gallium nitride ("GaN"). The Group is committed to accelerating its research and development and expansion in the application of GaN related products, with an aim to become a leading semiconductor company with the integration of design, manufacturing and sales of semiconductor chips, as well as providing total solutions with higher efficiency and competitive system cost.For more details, please visit www.hg-semiconductor.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Honda and GS Yuasa Reach Basic Agreement Toward Collaboration for a High-capacity, High-output Lithium-ion Battery JCN Newswire

Honda and GS Yuasa Reach Basic Agreement Toward Collaboration for a High-capacity, High-output Lithium-ion Battery

TOKYO, Jan 24, 2023 - (JCN Newswire via SEAPRWire.com) - Honda Motor Co., Ltd. (Honda) and GS Yuasa International Ltd. (GS Yuasa) today announced that they have reached a basic agreement toward collaboration for a high-capacity, high-output lithium-ion battery. The two companies will discuss specifics with the goal of establishing a joint venture company by the end of 2023. In order to address the rapidly growing demand for batteries, the two companies reached this agreement to work toward the joint research and development of lithium-ion batteries and battery production methods that will be highly competitive in the global market, as well as the establishment of a supply chain for key raw materials and a highly-efficient battery production system.Based on the agreement, the two companies will work toward the establishment of a joint venture company by discussing a broad scope of collaborations including the following: - Research and development of a high-capacity, high-output lithium-ion battery, primarily for EV use, and the required production methods- Establishment and management of intellectual properties including patents related to the joint research and development- Planning for products that utilize technologies resulting from the joint research and development, and planning for the required sales channels- Designing of an efficient production operation including the supply chain for key raw materialsComments by Toshihiro Mibe, Director, President and Representative Executive Officer of Honda Motor Co., Ltd."Honda is striving to realize carbon neutrality for all products and corporate activities Honda is involved in by 2050. Honda and GS Yuasa have already been working together on lithium-ion batteries for hybrid electric vehicles (HEVs), and this new collaboration will further accelerate Honda's electrification strategies toward the achievement of our carbon neutrality goal."Comments by Osamu Murao, President and Representative Director of GS Yuasa International Ltd."Based on our corporate philosophy of 'Innovation and Growth,' GS Yuasa has been taking on challenges to create energy technologies while amassing a broad range of knowledge and know-how related to batteries. Through this new collaboration with Honda, we will contribute to further diffusion of electric vehicles, offer enhanced comfort and peace of mind to customers worldwide and strive to create new value for the realization of carbon neutrality." Copyright 2023 JCN Newswire. All rights reserved. (via SEAPRWire)
More
ACROMETA receives LOA for S$6.1 million design and build works from a global clinical research organisation ACN Newswire

ACROMETA receives LOA for S$6.1 million design and build works from a global clinical research organisation

SINGAPORE, Dec 30, 2022 - (ACN Newswire via SEAPRWire.com) - AcroMeta Group Limited, an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, has received a letter of award ("LOA") for the design and build of laboratory and office space worth approximately S$6.1 million from a global clinical research organisation that helps companies conduct clinical development of drugs or medical devices (the "Project").The Project site work is commencing soon and a binding contract would be executed in due course. In the unlikely event that the execution of contract is not followed through, the Group is safeguarded as it would be entitled to claim a maximum value of approximately S$1.8 million for value of works performed.Said Mr Lim Say Chin, Executive Chairman, "We are greatly encouraged that the Project involves a new customer in the biotechnology space. This speaks of the confidence that our customers have in our capabilities. We will continue to work hard towards delivering quality services, leveraging on our established track record and proven expertise as controlled environment specialist engineers."The Project is expected to contribute positively to the earnings per share and net tangible assets per share of the Group for the current financial year ending 30 September 2023.To the best of the Directors' knowledge, none of the Directors and controlling shareholders of the Company have any interests, direct or indirect, in the Project, other than through their respective shareholdings in the Company.About ACROMETA Group Limited (SGX Stock Code: 1CH1)ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.ACROMETA's business is divided into two main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies. The company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.Media and Analysts Contact:ACROMETA Group LimitedMr. Jerry TanChief Financial OfficerTel: +65 6415 0574Email: jerry.tan@acromec.comWaterbrooks Consultants Pte LtdMr. Wayne KooTel: +65 6958 8008 / +65 9338 8166Email: wayne.koo@waterbrooks.com.sgEmail: query@waterbrooks.com.sgThis media release has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.ACROMETA Group Limited: [SGX: 43F] [BIC: ACRO:SP] [RIC: ACRO.SI], www.acrometa.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases JCN Newswire

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases

TOKYO, Dec 15, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases. The two organizations have been collaborating in AD research. The Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicine, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody E2814 for the treatment of dominantly inherited Alzheimer's disease (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab (generic name, development code: BAN2401) was selected as the background anti-amyloid agent.The collaboration strategically combines Washington University scientists" expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai's extensive experience in drug discovery and development. Using human biology, the aim is to create multiple novel therapeutic candidates as well as discover and identify biomarkers within the next five years. Eisai will have the option rights to develop and commercialize any compounds and biomarkers that meet certain criteria in terms of research and development milestones. In the case that Eisai chooses to exercise the options, Eisai will pay Washington University milestone payments and royalties on future sales of each licensed compounds.Dr. Teiji Kimura, Ph.D., Academia and Industry Alliance Officer, Deep Human Biology Learning (DHBL) Office of Eisai, commented, "Patients living with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, struggle with critical unmet medical needs, which is the reason neurology is a key therapeutic area for Eisai. By collaborating with world-leading research institutions such as Washington University in St. Louis, Eisai is working to fulfill our human health care mission and provide potential new and targeted disease-modifying therapies with the ultimate goal of achieving a world free of neurodegenerative disease."About Washington University School of MedicineWashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,700 faculty. Its National Institutes of Health (NIH) research funding portfolio is the fourth largest among U.S. medical schools, has grown 54% in the last five years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,790 faculty physicians practicing at over 60 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children's hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.Media Inquiries:Public Relations Department, Eisai Co., Ltd.+81-(0)3-3817-5120Eisai Inc (U.S.)Libby Holman 201-753-1945Libby_Holman@eisai.com Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing ACN Newswire

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

SINGAPORE, Dec 6, 2022 - (ACN Newswire via SEAPRWire.com) - Leading pharma companies GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research (A*STAR); National University of Singapore (NUS); Nanyang Technological University, Singapore (NTU Singapore) and its innovation and enterprise company, NTUitive; and Singapore Institute of Technology (SIT) to boost Singapore's biologics manufacturing capabilities.BioPIPS MOU signing ceremonyTheir partnership will be formalised through the Biologics Pharma Innovation Programme Singapore (BioPIPS), a consortium initiated by A*STAR with support from the Singapore Economic Development Board (EDB).BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines. Amid the COVID-19 pandemic, biologics and vaccines played a critical role globally in preventing severe disease and saving lives.The consortium will bring together leading industry experts and Singapore's research ecosystem to enhance manufacturing productivity, improve operational efficiency and achieve sustainability goals. The consortium ultimately aims to make Singapore's biologics manufacturing capabilities best-in-class and well-positioned for the introduction of new products and novel manufacturing technologies."New opportunities will emerge as the biomanufacturing industry undergoes major changes brought about by the rapid pace of digitalisation, Industry 4.0, and the need for greater sustainability. As Singapore makes biopharma production a priority area in its Research, Innovation and Enterprise 2025 Plan, A*STAR aims to contribute our R&D capabilities through BioPIPS to help make the local biomanufacturing industry become more agile and better positioned to benefit from new products and technologies," said Professor Lim Keng Hui, Assistant Chief Executive, Science and Engineering Research Council, A*STAR."Riding on the success of PIPS, BioPIPS aims to enhance Singapore's innovation capabilities in biologics and vaccines manufacturing by leveraging the strengths of our leading pharmaceutical companies and institutes of higher learning. The programme will develop highly productive, sustainable and advanced production technologies and solutions. We look forward to deepening partnerships with like-minded companies to strengthen Singapore's position as a global biopharma manufacturing hub," said Mr Tan Kong Hwee, Executive Vice President, EDB.Specifically, BioPIPS will have three workstreams.- The Sensing and Modelling workstream aims to harness machine learning and mechanistic modelling technologies, together with smart sensors, to enable simplified and faster workflows. Data analytics will enable the effective translation of process knowledge gained into performance improvements, which in turn benefits the overall manufacturing process.- The Sustainability workstream focuses on tackling sustainability challenges in biologics and vaccines manufacturing, which typically utilises single-use (disposable) equipment due to the extremely sterile environment needed for product purity. This workstream will explore the use of novel materials and circular economy approaches to address this challenge, as well as models to promote more sustainable and resilient supply chains.- The Compliant Agility workstream focuses on the removal of manual tasks to achieve greater productivity in the manufacturing facilities while maintaining compliance status, by using solutions like robotics and advanced analytics.BioPIPS is in line with Singapore's Manufacturing 2030 vision, which aims to anchor leading manufacturing activities to grow the country's manufacturing value-add by 50 per cent from 2020. The solutions developed through BioPIPS will also enhance Singapore's capabilities to meet the growing global demand for biologics and vaccines, as well as equip pharmaceutical companies here with the resources to scale up and respond more rapidly to future pandemics."By collaborating to tackle common challenges, we can leverage diverse skills and capabilities to create a sustainable manufacturing environment in Singapore. We also look forward to developing new ways to monitor and control our processes and automate our manufacturing operations," said Chan Siong Wan, Site Director, GSK."Sanofi is building a next generation manufacturing site, the EVolutive Facility, in Singapore, which will bring advanced digital and modular vaccine production capabilities to the Asia region. The BioPIPS programme's focus on transforming biologics and vaccines manufacturing through pre-competitive partnerships is aligned with Sanofi's vision for the EVolutive Facility, to continuously push the envelope of innovation for biopharmaceutical manufacturing," said Mr Koh Liang Hong, Site Head, EVolutive Facility, Sanofi."The objectives of BioPIPS are aligned to Takeda's ambitions of being net carbon zero in our operations by 2035 and how we can tap on data, digital and technology to transform our manufacturing site. We look forward to this partnership with Singapore's research ecosystem to further strengthen our capabilities, and discover new and sustainable ways to develop and manufacture innovative medicine to deliver on Takeda's commitment to Patient, People and Planet," said George Lam, Site Head, Takeda Manufacturing Singapore.BioPIPS builds on the consortium model established by the Pharma Innovation Programme Singapore (PIPS), which was set up to boost Singapore's capabilities for manufacturing of small molecule drugs made of chemical compounds."NUS is delighted to be a member of BioPIPS, contributing our capabilities in areas such as biocatalysis, reactor manufacturing, and digital factory. By leveraging the complementary strengths of A*STAR, EDB, the academia and the pharmaceutical industry, we can create a strong technology foundation for innovations that will bring about compelling improvements in productivity, operational efficiency and sustainability practices in Singapore's biopharma manufacturing sector," said Professor Thorsten Wohland, Director, Research Governance and Enablement, Office of the Deputy President (Research and Technology), NUS."The Covid-19 pandemic has highlighted the need for the biomanufacturing industry to be innovative and agile when dealing with challenges, including future pandemics and disease outbreaks. At the NTU Smart Campus, our scientists have been pioneering advanced solutions such as breathalysers that can detect Covid-19 in two minutes and a semi-autonomous robot that can disinfect surfaces. Such groundbreaking research underlines our commitment to the NTU 2025 strategic plan that aims to solve some of humanity's grand challenges, including addressing the needs and challenges of healthy living and ageing. With our strengths in interdisciplinary research and innovation, we hope to play our part to bolster the sector's manufacturing productivity and operational efficiency in a sustainable manner. We look forward to achieving meaningful results with our partners through this national consortium," said Professor Peter Preiser, Associate Vice President (Biomedical and Life Sciences), NTU Singapore."SIT is excited to be part of BioPIPS, which will inject next-generation process innovation into the local pharmaceutical industry. This partnership will allow SIT to strengthen its applied research capabilities in sustainable biopharma manufacturing technologies. Under this initiative, SIT will explore opportunities to work with manufacturers to apply digitalisation for process optimisation and better regulatory oversight while incorporating environmental considerations to progress production processes for the pharmaceutical industry," said Associate Professor Susanna Leong, Vice President (Applied Research), SIT.Image https://www.acnnewswire.com/topimg/Low_astar20221206.jpgA/Prof Susanna Leong, Vice President (Applied Research), SIT; Prof Thorsten Wohland, Director, Research Governance and Enablement, Office of the Deputy President (Research and Technology), NUS; Prof Ng Huck Hui, Assistant Chief Executive, Biomedical Research Council, A*STAR; Mr Chan Siong Wan, Site Director, GSK; Mr Tan Kong Hwee, Executive Vice President, EDB; Mr Koh Liang Hong, Site Head, EVolutive Facility, Sanofi; Mr George Lam, Site Head, Takeda Manufacturing Singapore; Prof Lim Keng Hui, Assistant Chief Executive, Science & Engineering Research Council, A*STAR; Prof Peter Preiser, President's Chair in Biological Science & Associate Vice President (Biomedical and Life Sciences), NTU Singapore; Mr David Toh, Director and Chief Executive Officer, NTUitive [L-R]For media queries and clarifications, please contact:Owen Sia (Mr)Assistant Head, Corporate CommunicationsAgency for Science, Technology and ResearchTel: +65 6517 7866Email: owen_sia@hq.a-star.edu.sgFabius Chen (Mr)Senior Manager, Corporate Marketing and CommunicationsSingapore Economic Development BoardTel: +65 6832 6125Email: fabius_chen@edb.gov.sgAbout the Agency for Science, Technology and Research (A*STAR)The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.Follow us on Facebook: https://www.facebook.com/ASTARSG/LinkedIn: https://www.linkedin.com/company/astarsg/Instagram: https://www.instagram.com/astarsg/YouTube: https://www.youtube.com/astartvTwitter: https://twitter.com/astarsgAbout the Singapore Economic Development BoardThe Singapore Economic Development Board (EDB), a government agency under the Ministry of Trade and Industry, is responsible for strategies that enhance Singapore's position as a global centre for business, innovation, and talent. We undertake investment promotion and industry development, and work with international businesses, both foreign and local, by providing information, connection to partners and access to government incentives for their investments. Our mission is to create sustainable economic growth, with vibrant business and good job opportunities for Singapore and Singaporeans. For more information on EDB, please visit www.edb.gov.sg. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Global Innovation & Value Summit (GIVS2022): Why ESG Evaluation Matters, to be held November 18 JCN Newswire

Global Innovation & Value Summit (GIVS2022): Why ESG Evaluation Matters, to be held November 18

KYOTO, Japan, Nov 17, 2022 - (JCN Newswire via SEAPRWire.com) - Opening the COP27 Conference, UN Secretary-General Antonio Guterres chided world leaders about their ongoing inaction, warning that immediate, real and tangible action is required to address the climate crisis, or "we are on the highway to hell, with our foot on the accelerator."IAFOR GIVS Symposium 2022 to be held on November 18: https://givs.iafor.org/ According to Prof. Philip Sugai, Director of the Value Research Center (VRC) in Kyoto, Japan, "Corporations are now pressed to answer to a more diverse group of stakeholders, and while there are more than a hundred different types of ESG (Environment, Social, and Governance) evaluation and reporting systems, none yet offer the guidance and strategic value to businesses that are required to address the many complex issues facing business leaders today."The 2022 IAFOR Global Innovation and Value Summit (GIVS) is focused on providing one possible offramp from Guterres's highway to hell, showcasing a new approach to measure and monitor the value created and destroyed by companies irrespective of their size, industry or location. The Value Model offers a powerful alternative to currently available ESG evaluation systems (ie MSCI, Bloomberg and FTSE4Good) with a new, more holistic approach for measuring, managing and creating value for a diverse group of stakeholders not yet found in any single existing ESG or sustainability reporting framework. The 2022 GIVS event, "The Future of ESG and Value: Why ESG Evaluation Matters", will include two panel sessions in the areas of sustainability, purpose, and value. Prof. Toshiya Hoshino, Director, ESG-Integration Research and Education Center (ESG-IREC) at Osaka University's Osaka School of International Public Policy (OSIPP) and former Ambassador and Deputy Permanent Representative of Japan to the United Nations, will deliver the keynote speech. Having attended COP27 in Sharm el-Sheikh, Egypt, he will bring to the Symposium valuable insights on the difficult international negotiations at the COP27 conference.The first panel session will cover critical issues that business leaders, regulators and policy makers need to focus on over the coming 12-24 months related to the implementation of ESG and sustainability within their organizations, and introduces the VRC Value Model. The second panel will explain the VRC Value Model and introduce the Value Model certification course.The full agenda for the 2022 IAFOR GIVS event ( https://givs.iafor.org/ ) is as follows:13:00-13:30: Keynote Address - Prof. Toshiya Hoshino, Director, ESG-Integration Research and Education Center, Osaka School of International Public Policy (OSIPP), Osaka University 13:30-15:00: Session 1 - Moderator: Prof. Haruko Satoh, OSIPP; Value Measurement & Sustainability, Challenges & Opportunities (15 min presentation each, 30-minute discussion)- Speaker 1: Mr. Paul Beddie, International Ambassador, SAP - Speaker 2: Dr. Flocy Joseph, Singapore Management University- Speaker 3: Prof. Philip Sugai, Value Research Center (VRC), Doshisha University, Kyoto, Japan15:00-15:15: Break15:15-16:45: Session 2 - Introducing the Value Model and Value Model Certification Program- Speaker 1: Prof. Philip Sugai, Value Research Center (VRC)- Speaker 2: Dr. Kumar Iyer (VRC)- Speaker 3: Seitaro Owada (EcoRing)16:45-17:00: Concluding address - Mr. Setsu Mori, CEO & Editor-in-Chief, Alterna MagazineThis course will be provided by the Value Research Center, in collaboration with the ESG-Integration Research and Education Center (ESG-IREC) at Osaka University's Osaka School of International Public Policy (OSIPP), as well as the VRC Juku, a new membership organization dedicated to thought leadership in value creation and measurement, with D-Bridge, a non-profit organization at Doshisha University (Kyoto, Japan).The time for action to attain UN Sustainable Development Goals (SDGs) is growing more critical every day. As neoliberal capitalism's excessive focus on company and shareholders' profits is increasingly identified as a major driver of environmental destruction as well as a host of social and economic inequality issues, today's business leaders are evaluated not only on their ability to create profitable outcomes, but to do so while simultaneously delivering real, tangible value for the other stakeholders, which include customers, employees, partners, society and ultimately the planet.About IAFORFounded in 2009, The International Academic Forum (IAFOR) is a politically independent non-partisan and non-profit interdisciplinary think tank, conference organiser and publisher dedicated to discussion, awareness and exchange through educational interaction and academic research. Based in Nagoya, Japan, its research centre is in the Osaka School of International Public Policy (OSIPP), Osaka University. Visit https://iafor.org/.About VRCThe Value Research Center (VRC) at Doshisha University in Kyoto, Japan was established in November 2021. Its mission: to develop a practical system called The Value Model, enabling organizations to measure, monitor, assess and report on their impacts to 7 key stakeholders: the organization itself, its shareholders, employees, customers, partners, society, and the planet.The VRC enhances The Value Model continuously, integrating new frameworks as they are introduced, bringing greater transparency, objectivity and measurability to value creation - in ways we don't often see. The VRC Value Model gives government and industry the eyes to see impacts they're actually having, and the ability to fix what's broken, and enhance what they're doing well. Visit www.valueresearchcenter.com.About ESG-IRECThe Osaka University Graduate School of International Public Policy - ESG Integration Research and Education Center (ESG-IREC) conducts research on practical implementable "ESG integration" models in corporate and business activities for the creation of a more sustainable future. Visit www.osipp.osaka-u.ac.jp/en/. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy ACN Newswire

Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy

SYDNEY, AU, Nov 11, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, is sponsoring BioCentury-BayHelix East-West Summit 2022, and Novotech's Chief Commercial Officer Barry Murphy is Session Chair for the expert panel on How to Build and Finance an East-West MRCT Strategy Workshop at the Summit (14-16 November 2022).Novotech is sponsoring the Networking Reception and Dinner.Workshop details:Global Development Workshop: How to Build and Finance an East-West MRCT StrategyNovember 15, 20222:30 PM - (PACIFIC TIME ZONE) BioCentury-BayHelix East-West Summit 2022https://conferences.biocentury.com/china-healthcare-summit/schedulePanelists are:- PATRICIA KEEGAN, M.D.: Chief Medical Officer, Junshi Biosciences- KE LIU, M.D., PH.D.: Chief Development Officer, Marengo Therapeutics- ROGER LUO, PH.D.: Chief Development Officer, Overland Pharmaceuticals- PEONY YU, M.D.: Chief Medical Officer, Apollomics Inc.Novotech has significant real-world experience in East-West MRCT strategy after more than 2 decades managing clinical research programs for biotechs across Asia Pacific and the US.Commenting on Novotech's experience, Chief Commercial Officer Barry Murphy said the right drug development pathway supports investor attraction and a successful clinical program."Local regulatory knowledge and expertise will accelerate early clinical programs, while a global perspective with a focus on US FDA and NMPA requirements, will support key market approvals. Strategies for an East-West MRCT include:- Companies should engage with the US FDA and NMPA early to confirm guidance on their clinical roadmap.- Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market. - For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favourable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.Novotech regularly produces expert reports on East-West strategies. A new publication is now available for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China.The report details regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful US FDA approval pathway. Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approvalNovotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the US FDA and NMPA approval process, avoiding delays and additional costs.Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia Contactcommunications@novotech-cro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company ACN Newswire

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

HONG KONG, Nov 4, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, Mr. Shanchun WANG has been appointed as the President (China) of the Company. Mr. Wang will mainly be responsible for the China operation.Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company. Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization. He is a specialist that granted the special government allowances of the State Council and awarded as a national model worker, a Jiangsu Province Technology Advanced Worker, a Jiangsu Province Model Labour, a winner of the Shanghai Technology Advancement First Honour Award, a Jiangsu Province Outstanding Entrepreneur, a Jiangsu Province Young and Middle-aged Expert with Outstanding Contribution, a Jiangsu Advanced Individual with Outstanding Contribution in Manufacture etc. Mr. Shanchun WANG said that: "Under the leadership of Dr. Shui On LEUNG, SinoMab has gathered a very strong R&D force, forged a unique B-cell therapeutic platform, and prospectively launched a pipeline with a series of potential key products, with truly internationally recognized original innovation strength. At the same time, SinoMab's dedication to the field of autoimmune diseases and its vision of growing into a global leader in novel treatments of immunological diseases is highly consistent with the development model of my service enterprises in the past, which is also an important reason why I chose to join SinoMab." Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company. Our Group has been engaging extensively in the field of autoimmune disease and with the mission of growing into a global leader in the novel treatments of immunological diseases. We have a strong research and development capabilities. Leveraging on our Group's B-cell therapeutic platform, Alarmins-pathway therapeutic platform and selective T-cell therapeutic platform, the Group has a strategic plan in expanding and diversifying our product pipeline. We believe that Mr. Wang's rich experience in the pharmaceutical industry for more than 30 years, and as one of the leaders in the biotech industry in China, will help expediting the Company's development from a global drug research and development enterprise to a biopharmaceutical company bearing commercialization capabilities and international perspective. Mr. Wang's engagement as the President (China) of the Company while also subscribing shares of the Company also reflects the confidence and commitment of Mr. Wang and our senior management towards the long-term and sustainable growth of the Group, and the continuous support of our senior management will be beneficial to the long-term business development of the Group."The Company entered into a subscription agreement with Mr. Wang earlier. Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares. This reflects his confidence and commitment towards the long-term and sustainable growth of the Group. About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus, non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Clinical Research Opportunities in China and the Path to USFDA Approval – Whitepaper ACN Newswire

Clinical Research Opportunities in China and the Path to USFDA Approval – Whitepaper

SYDNEY, AU, Oct 25, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, and GlobalData have published the latest China biotech landscape analysis with expert guidance on pathways to USFDA approval for biotechs conducting research in China.Download whitepaper here https://novotech-cro.com/whitepapers/china-biotech-landscape-opportunities-china-and-path-usfda-approval The report was prepared for international biotechs considering China for their clinical research, as well as China biotechs conducting research in China, and the relevant processes required for USFDA approvals.Novotech's Vice President, Global Head of Clinical Services Dr. Yooni Kim said: "China presents exceptional clinical opportunities with vast populations and word-class research facilities and KOLs. This concise analysis of the pathway to USFDA approval expertly informs clinical stage biotechs about the China research benefits and how to manage any challenges. The report details the regulatory requirements for biotechs including NDA and IND processes as well as ex-US research guidance for a successful USFDA approval pathway. Novotech, with experienced clinical teams in China and the US, can provide the relevant regulatory knowledge and drug development pathways specifically designed to support the USFDA approval process, avoiding delays and additional costs."The key learnings from the report are:- Companies should engage with the USFDA early and formally to confirm guidance on their clinical roadmap.- China's clinical development regulations are aligned with the USFDA regulations and present significant benefits for biopharma companies.- Biopharma companies should take advantage of China's revised regulatory framework around acceptance of foreign clinical trials data for drug approval, making it easier for foreign companies to enter the Chinese market.- For biopharma companies looking to enter China, China's pharmaceutical market has advantages such as conducting first-in-human trials (FIH) and utilization of overseas clinical trial data for clinical trial application (CTA) filing, leveraging expedited clinical development pathways for accelerating the approval process; implementation of the Marketing Authorization Holder (MAH) system, favorable government policies to enhance domestic and global innovation encourages foreign direct investments (FDIs) in R&D that benefit the overseas companies.- Chinese biotech companies can enter developed markets in the US and Europe through strategic partnerships or by setting-up their own operations in these markets.Novotech has operations across the Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late-phase biotech clinical research. The company has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership, and flexibility. Consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact Media ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Fujitsu, Keio Research Institute at SFC lay foundation for a Trustable Internet JCN Newswire

Fujitsu, Keio Research Institute at SFC lay foundation for a Trustable Internet

TOKYO, Oct 13, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu and the Keio Research Institute at SFC today published a white paper on the concept of a Trustable Internet, which enables verification of the authenticity of data on the Internet in a general-purpose manner by adding a new layer, the so-called "Endorsement Layer," between the existing Internet layer and the app/web layer. The white paper contains the results of research conducted at the "Trusted Internet Architecture Laboratory"(1).Figure: Endorsement Layer ImageTrustable Internet will enable users to confirm the credibility of various data on the Internet that has previously been difficult to verify based on additional information related to the generation and processing of the data, information on confirmation and evaluation by third parties that have viewed the data, and information on physical space related to the data (sensor data, etc.). This enables users to judge the credibility of data from a variety of perspectives to ultimately prevent the use of unverified data and the spread, unintentional or otherwise, of false and unverified information ("fake news").Moving forward, Fujitsu and the Keio Research Institute at SFC will promote the development of new technologies at the Trusted Internet Architecture Laboratory with the aim to contribute to the realization of a "Trustable Internet" by fiscal 2028 by implementing an "Endorsement Layer," apps and browser functions to verify the authenticity of data from users' devices.Fujitsu and the Keio Research Institute at SFC initially presented the "Trustable Internet" concept at the W3C (World Wide Web Consortium) annual meeting and the W3C TPAC 2022 meeting (September 12-16, 2022) and defined the concept based on the opinions of various experts.BackgroundThe intentional spread of false or unverifiable information and data on the internet represents a growing threat to society, and by some estimates so-called "fake news" costs the global economy at least $78 billion per year(2).Conventional methods to ensure the authenticity of data include data tracking systems such as document approval management systems and luggage delivery tracking systems that use individual methods to record data trails.However, the verification of large amounts of information on the Internet remains a difficult task, highlighting the need for a general-purpose method to prove the authenticity of data.To address these issues, Fujitsu and the Keio Research Institute at SFC published their white paper outlining the concept of a "Trustable Internet" as a result of the research at their joint research base, the Trusted Internet Architecture Laboratory, which was established in April 2022. Through their joint research, the two parties aim to promote R&D of technologies that enable the exchange of trusted data on the Internet by combining their knowledge and know-how to resolve issues related to data authenticity.The Keio Research Institute at SFC, the Japanese base of the W3C, has been promoting standardization of web technologies since the 1990s, and is at the forefront of the global standardization of the Internet through various activities. Fujitsu has been an active player in IT since the early stages of the Internet, and possesses various technologies and knowledge, including well-established security-related technologies as well as recently developed leading-edge technologies including a self-sovereign identity technology to interconnect different identity infrastructures.OutlineThe concept of a Trustable Internet represents a new approach to simplify the verification of the authenticity of data on the Internet. Within this approach, the originator or a third party can add background information as authenticity proof of the original data and verify data by adding an "Endorsement Layer" to the Internet layers that is shared with the users. This configuration can be implemented without impacting the existing Internet, and allows Internet users to use the Internet and applications as usual, and, if necessary, obtain necessary information to verify the authenticity of data and information.Additional information that can be used to verify the authenticity of data can be provided by people and devices at the time of data generation (information on the name, affiliation, and qualifications of the creator of the data [person or corporation] or used device, place, and date and time). Further, additional information including verifications and evaluations of third parties such as independent experts and information obtained from physical spaces including sensor measurements can be added after the data is generated. Users can search and check additional information necessary to verify the authenticity of data on the Internet in the Endorsement Layer, where information will be stored as graph data.In this way, users can evaluate data authenticity from a multifaceted perspective, which makes data-driven decisions more accurate and helps to prevent the spread of unverified data.Trustable Internet White Paper v 1.0 (PDF format) (bit.ly/3yyoKqo)Trustable Internet concept video (bit.ly/3CTJ1cm)Trusted Internet Architecture Laboratory Organization- Director: Professor Osamu Nakamura (Faculty of Environment and Information Studies, Keio University)- Associate Director: Professor Jun Murai (Keio University)- Associate Director: Project Professor Shigeya Suzuki (Graduate School of Media and Governance, Keio University)- Researchers from the Keio Research Institute at SFC and Fujitsu (approx. 20 members)(1) Trusted Internet Architecture Laboratory :The Trusted Internet Architecture Laboratory was established as a part of the activities of the Fujitsu Small Research Laboratory; Fujitsu researchers will work indefinitely or for extended periods of time at the Trusted Internet Architecture Laboratory, aiming to accelerate joint research, discover new themes, develop human resources, and build medium- to long-term relationships with the university.(2) Fake news imposes a cost on the global economy of at least $78 billion per year :The Economic Cost of Bad Actors on the Internet: Fake News | 2019About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About the Keio Research Institute at SFCThe Keio Research Institute at SFC was established in 1996. In its capacity as an academic entity and research institute affiliated with the Graduate School of Media and Governance, Graduate School of Health Management, Faculty of Policy Management, Faculty of Environment and Information Studies, and Faculty of Nursing and Medical Care, the institute serves as a platform for promoting advanced research activities and collaborative initiatives involving the community and local regions. By 2021, the institute had more than 40 laboratories (transdisciplinary research groups with advanced research missions) and more than 30 SFC research consortiums (joint research deployed by the Keio Research Institute at SFC in conjunction with a number of external organizations), and together with approximately 500 senior and guest researchers from various industries, government, and academia, aims to develop unique research to create a vital society. In this manner, the Keio Research Institute at SFC has a wealth of experience and a proven track record in the creation of pioneering knowledge through collaborations among industry, government, and academia. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities ACN Newswire

Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities

PETALING JAYA, Malaysia, Oct 12, 2022 - (ACN Newswire via SEAPRWire.com) - MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals.Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian GenomicsThe National Institutes of Health (NIH), the research arm under the Ministry of Health Malaysia, comprises six research institutes that focus on biomedical research, public health and epidemiology, clinical research, behavioural health research, health management and health policies. The NIH is mandated to conduct high-impact health research to improve the quality of life of the Rakyat. The health research conducted by the NIH is in line with the Health Research Priority Areas for each five-yearly Malaysia Plans.MGRC-T specialises in genomics and biopharmaceutical services with proprietary know-how and intellectual property related to the research, development, and processing of genetic screening tests, as well as the manufacturing of cell therapies, including immunotherapy for various types of cancer.Dato' Alvin Joseph Nesakumar, Executive Director of Malaysian Genomics, said, "The cooperation agreement enables us to explore ways that we can work together with NIH to improve the quality of our genomics and biopharmaceutical services that can contribute to improving the health of the Rakyat. We consider this collaboration a good step in encouraging and promoting research in genomics and biopharmaceuticals that will be mutually beneficial."Dr S Asmaliza Ismail, Manager of the NIH said, "We welcome this agreement as we are keen to work with specialists such as Malaysian Genomics to exchange knowledge in various fields of medical research. We believe that by working and pooling our resources together, we can bridge the gaps in expertise and experience."Under this agreement, the parties will explore joint training in the field of medical research, exchange research materials, and partake in scientific data presentation and publication. Additionally, the agreement will enable the exchange of experts and personnel, including postgraduate research and students on adjunct appointments, short- and long-term research attachments, co-supervision of students conducting research and internships, as well as other areas of cooperation to be mutually decided.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan JCN Newswire

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

TOKYO, Oct 4, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of its medium-term business plan "EWAY Future & Beyond", it has completed construction of the new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan.External view of EMITSEMITS will be Eisai's global base for formulation and modality research. In recent years, Eisai's drug discovery targets have expanded to include modalities such as antibodies, antibody drug conjugates (ADCs), and nucleic acid drugs, in addition to conventional small molecule compounds. At EMITS, Eisai will strengthen its injectable drug formulation development research function and drug delivery system (DDS) development function, including liposomal and lipid nanoparticle formulations, and address the development of various modalities. The following initiatives will be implemented. - Elevating the quality and speed of formulation process research through introduction of a state-of-the-art manufacturing data management system and utilization of AI- Installation of facilities that also enable the manufacturing of clinical trial materials in order to manufacture investigational injection drugs in-house- Introduction of rapid microbial testing methods for advanced microbiological control and sterility assurance- Enhancing collaboration with the creation of flexible space that can also be used for collaborative research with external partners and technologiesThrough these efforts, Eisai aims to elevate the quality of the technology and knowledge of its formulation research function, and to become a base for disseminating innovation, technology, and solutions relating to formulations. The aggregate investment in the construction of EMITS is approximately 10 billion Japanese yen. The Kawashima Industrial Park is Eisai's global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing. Through the construction of EMITS, Eisai aims to elevate the quality of its formulation research and formulation manufacturing, accelerate medicine creation activities, and ultimately further its contribution to improving the benefits of patients and their families. Media Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120For more information, visit www.eisai.com/news/2022/news202273.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Avance Clinical Wins International Health Award for Biotech CRO Services ACN Newswire

Avance Clinical Wins International Health Award for Biotech CRO Services

SYDNEY, AU, Sep 28, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier's Export Awards - International Health category. The award recognises excellence in clinical services exports.Avance Clinical CEO Yvonne LungershausenThe Premier of South Australia Peter Malinauskas, and Minister for Trade and Investment Nick Champion, presented the Premier's Export Awards to Avance Clinical CEO Yvonne Lungershausen at the awards industry event today. This follows Avance Clinical's selection as finalist for the Informa Pharma Intelligence Awards 2022 Best Contract Research Organization in APAC. Avance Clinical, which is backed by global private equity firm The Riverside Company, recently acquired a leading CRO in North America to expand services and offer their biotech clients US sites for later phase studies. CEO Yvonne Lungershausen said Avance Clinical is now the leading Australian-based biotech CRO with US operations. "We are honoured to be selected for the award. We are a major employer with more than 220 staff and we bring significant biotech clinical research business into South Australia and Australia. Clinical research is a high-value export that keeps our medical, research, and biopharma sectors at the forefront of international knowledge and innovation. The majority of our clients are from North America, the EU, and Asia so we really are an internationally-focused organisation. Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients and we are very proud of our growth and success in recent years."The company provides global regulatory standard clinical research services across all phases to the international biopharma industry. Avance Clinical is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) for vaccines and GMO therapies clinical trials."We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Find out more:- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.comAbout Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for more than 24 years.Pre-clinical through to Phase 1 and 2Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah ACN Newswire

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

PETALING JAYA, Malaysia, Sep 21, 2022 - (ACN Newswire via SEAPRWire.com) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw MinUnder the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will assist in strengthening the teaching and research activities of the undergraduate programme at UMS' Faculty of Science and Natural Resources.This cooperation will enable the exchange of research resources and ideas to enhance the quality of research at UMS, as well as create opportunities for students from the Faculty of Science and Natural Resources to serve their internship period at MGRC or Genotec.Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the National Biotechnology Policy 2.0 launched recently focusing on agriculture and food security, healthcare and wellbeing, as well as industrial and the circular economy."The Dean of the Faculty of Science and Natural Resources, UMS, Professor Dr. Jualang Azlan Gansau said, "UMS is actively engaging in research as well as teaching activities and the involvement of industry is crucial in ensuring the relevance of such activities conducted at the University."The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Value Research Center (VRC) publishes August White Paper: The VRC Value Model & EFRAG ACN Newswire

Value Research Center (VRC) publishes August White Paper: The VRC Value Model & EFRAG

KYOTO, Japan, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Companies and sustainability teams need a new model for measuring and managing stakeholder impacts, as claims of corporate greenwashing and value washing increase daily. The Value Research Center (VRC) at Doshisha University in Kyoto, Japan has announced the publication of its 2022 August White Paper, focusing on the European Financial Reporting Advisory Group (EFRAG's) latest disclosure drafts for sustainability reporting, and how this model aligns with and deepens the overall quality of the VRC Value Model.The Value Research Center (VRC) publishes 2022 August White Paper: The Value Model & EFRAGAccording to Professor Philip Sugai, Director of the Value Research Center, "After integrating EFRAG's 114 draft disclosure requirements into the VRC Value Model, we were impressed with the scope of EFRAG's coverage of many of the Value Model's stakeholders, themes and goals. Especially with their push for companies to document their impacts using 'double materiality', we see a shift towards greater understanding of business decisions on individual stakeholder groups."SAP Japan International Ambassador Paul Beddie said, "The VRC In Kyoto has been working to organize the world's top ESG and Sustainability Reporting frameworks into a goal-based, value creation model that will help companies to create value across their key stakeholders. Companies around the world are in desperate need of a way to consolidate the alphabet soup of standards to reduce their workload on ESG reporting and focus more on the critical ESG outcomes they transformed their businesses to achieve. "The VRC's Value Model is a very effective tool for doing just that. The additional integration of the draft reporting standards from EFRAG should also help companies doing business in the EU to align their disclosures with the EU Taxonomy."With the publication of the August White Paper, the VRC will begin to collaborate with several of the world's leading companies in adopting the VRC Value Model, applying it to their own ESG and sustainability reporting requirements, and creating forward-looking sustainability strategies rather than backwards-focused disclosures.Professor Sugai will be hosting a session at the UNGA77 Science Summit, where he will discuss the VRC Value Model and its broader practical applications, together with a panel of experts from academia, government, and business.The UNGA77 Science Summit session, "Valuing Value: How any Organization Can Measure Stakeholder Value and "Ethical Capitalism" (https://ssunga77.sched.com/event/1AWkD), will be held on Sept 26 from 9:00 to 11:30 AM EST. Registration for the complete UNGA77 Science Summit is free and available at https://ssunga77.sched.com/tickets.The "2022 August White Paper: The Value Model & EFRAG" is available for download at the Value Research Center website: www.valueresearchcenter.com/publications.For more information about the Value Research Center and its projects, please visit: www.valueresearchcenter.com, or email Professor Philip Sugai at: info@valueresearchcenter.com .About the Value Research CenterThe Value Research Center (VRC) at Doshisha University in Kyoto, Japan was established in November 2021. Its mission: to develop a practical system for organizations to measure, monitor, assess and report on the impacts that they have on various stakeholder groups.The VRC continues to enhance its Value Model, integrating new frameworks as they're introduced, bringing greater transparency, objectivity and measurability to value creation - in ways we didn't see. The VRC Value Model gives government and industry eyes to see the impacts they're actually having, to fix what's broken, and enhance what they're doing well. For more information, visit www.valueresearchcenter.com. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

TANAKA Memorial Foundation to Offer Precious Metals Research Grants of up to 5 Million Yen

TOKYO, Sep 1, 2022 - (ACN Newswire via SEAPRWire.com) - The TANAKA Memorial Foundation (Representative Director: Hideya Okamoto) announced that it will take applications for research themes for FY2022 Precious Metals Research Grants between September 1 (Thu) and November 30 (Wed). Applications will be accepted from Japanese educational institutions and public research institutes conducting research and development using precious metals. In this 24th year of the research grant, recipients will receive 5 million yen for the Platinum Award, 2 million yen for the Gold Award, 1 million yen for the Silver Award, 1 million yen for the Young Researcher Award, and 300,000 yen for the Encouragement Award.Applications for the Precious Metals Research Grants are open to themes in all fields related to new technology and research and development in which precious metals can make a contribution. Applications can be submitted using the application form on the TANAKA Memorial Foundation website ( https://tanaka-foundation.or.jp ), and, after strict examination, award recipients will be announced at the end of March 2023.The TANAKA Memorial Foundation aims to contribute to the development and cultivation of new fields for precious metals and to the development of science, technology, and the social economy by conducting activities that enable more people to experience a prosperous society. This program is being implemented to help support the various challenges faced in the "new world opened up by precious metals." Last year, the research on "Enhancing development of model-based design and production technologies for electronic parts containing precious metals" won a Gold Award for being able to significantly contribute toward the development of processing technologies and improvement of performance through the development of model-based designs using numerical analysis methods - represented by methods such as the finite element method - to minimize cost and takt time related to product design, prototyping, and process design. Another Gold Award was presented for research and development on "Formation of backside power delivery network using precious metal wires" related to the formation of precious metal wires, which is an element technology for three-dimensional mounting that is gaining attention as an integration technology for advanced logic devices.Overview of the 2022 Precious Metals Research GrantsTheme:- Themes that involve any of the following: new technologies to which precious metals can make a contribution, research related to precious metals that will bring innovative evolution to products, or research and development of new products using precious metalsGrant Amounts:- Platinum Award: 5 million yen (1 award)- Gold Award: 2 million yen (1 award)- Silver Awards: 1 million yen (4 awards)- Young Researcher Awards: 1 million yen (2 awards)- Encouragement Award: 300,000 yen (several awards)* The grant amount is treated as a scholarship donation.* Awards may not be granted in some cases.* The number of awards is subject to change.Eligible Candidates:- Personnel who belong to (or work for) educational institutions in Japan (universities, graduate schools, or technical colleges) or public and related research institutions may participate.* As long as the applicant is affiliated with a research institution in Japan, the base of activity can be in Japan or overseas.* The Young Researcher Awards are for researchers under the age of 37 as of April 1, 2022.Application Period:- 9am, September 1, 2022 (Thu) - 5pm, November 30, 2022 (Wed)Application Method:- Enter the required information on the application form available on the TANAKA Memorial Foundation website ( https://tanaka-foundation.or.jp ) and upload details of the research (papers and supplementary material on the theme).Announcement:- Results will be announced on the TANAKA Memorial Foundation website around the end of March 2023.* TANAKA will contact the award recipients directly.Conditions:Research content that falls under any of the following- New technology related to precious metals- Research and development related to precious metals that bring about innovative evolution in products- Research and development of new products using precious metals* Precious metal refers to eight elements of platinum, gold, silver, palladium, rhodium, iridium, ruthenium and osmium.* If development is conducted jointly (or planned to be) with other material manufacturers, please indicate so.* Products that have already been commercialized, put to practical use, or that are planned are not eligible.Inquiries Concerning the Research Grant Program:Precious Metals Research Grants OfficeGlobal Marketing / R&D Supervisory Department, TANAKA Kikinzoku Kogyo K.K.22F Tokyo Building, 2-7-3 Marunouchi, Chiyoda-ku, Tokyo 100-6422E-mail: joseikin@ml.tanaka.co.jpTANAKA Memorial Foundation website: https://tanaka-foundation.or.jpTANAKA Memorial FoundationEstablished: April 1, 2015Address: 22F Tokyo Building, 2-7-3 Marunouchi, Chiyoda-ku, TokyoRepresentative: Hideya OkamotoPurpose of Business: To provide grants for research related to precious metals to contribute to the development and cultivation of new fields for precious metals, and to the development of science, technology, and the social economy.Areas of Business: Provision of grants for scientific and technological research related to precious metals. Recognition of excellent analysis of precious metals and holding of seminars and other events.TANAKA Kikinzoku Kogyo K.K.Headquarters: 22F, Tokyo Building, 2-7-3 Marunouchi, Chiyoda-ku, TokyoRepresentative: Koichiro Tanaka, Representative Director & CEOFounded: 1885Incorporated: 1918Capital: 500 million yenEmployees: 2,429 (as of March 31, 2022)Sales: JPY 389,646,820,000 (FY2021) Main businesses: Manufacture, sales, import and export of precious metals (platinum, gold, silver, and others) and various types of industrial precious metals products. URL: https://tanaka-preciousmetals.com* From the current consolidated fiscal year, the amounts of sales for some transactions are indicated as net values due to application of the Accounting Standard for Revenue Recognition.Press InquiriesTANAKA Holdings Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/This press release in PDF: https://www.acnnewswire.com/docs/files/20220901_EN.pdf Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Windows gain competitive edge over global warming ACN Newswire

Windows gain competitive edge over global warming

TSUKUBA, Japan, Sep 1, 2022 - (ACN Newswire via SEAPRWire.com) - A French-Japanese research collaboration has fabricated metal nanocomposite coatings that improve the insulating properties of window glasses. The new coating prevents a significant portion of near-infrared (NIR) and ultraviolet rays (UV) from passing through, while at the same time admitting visible light. The findings were reported in the journal Science and Technology of Advanced Materials.The nanoclusters are dispersed in a PVP matrix that is then coated on ITO glass to block NIR and UV rays while letting visible light pass through."Although the fabrication of a commercial products is still a long way ahead, our work demonstrated a significant improvement in UV and NIR blocking properties compared to previous research," says solid-state chemist Fabien Grasset, research director at the French National Centre for Scientific Research (CNRS)."Buildings account for a large part of global energy consumption," explains Grasset, "with a large amount of the annual energy consumption of a standard building going to cooling and/or heating systems to maintain indoor temperatures at comfortable levels." Scientists are looking for ways to develop window glass coatings that can block the entry of NIR radiation so that buildings, and even cars, can consume less energy to keep it cool inside. However, this needs to be done in a way that still allows visible light to enter. Ideally, harmful UV rays would also be blocked.To this end, the international French-Japanese research collaboration fabricated and analysed the performance of nanocomposites based on niobium-tantalum cluster compounds containing chloride or bromide ions.They found that chloride-based nanoclusters provided the best performance in terms of blocking NIR and UV rays and allowing the passage of visible light. NIR and UV blocking by the nanoclusters depended on their concentration, dispersion and oxidation state. By tuning these parameters, the team was able to improve the nanocluster performance.The nanoclusters were dispersed into a polyvinylpyrrolidone (PVP) matrix that was then coated onto indium-tin-oxide (ITO) glass. The combination increased the transmittance of visible light while reducing that of NIR and UV rays, relative to previous research. "These are very promising coating materials that block the most troublesome NIR wavelengths," says Grasset."We have a long history of Japanese-French collaboration," he continues. "We were already convinced that we are stronger working together by mixing our different cultures and ways of thinking. The international LINK project has reinforced this belief. We will continue to do our best to make further progress towards finding solutions for the global warming problem."Further informationFabien GrassetFrench National Centre for Scientific Research (CNRS)Email: fabien.grasset@cnrs.frResearch paper: https://www.tandfonline.com/doi/full/10.1080/14686996.2022.2105659About Science and Technology of Advanced Materials (STAM)Open access journal STAM publishes outstanding research articles across all aspects of materials science, including functional and structural materials, theoretical analyses, and properties of materials. https://www.tandfonline.com/STAMFor more information on STAM, contactDr. Mikiko TanifujiSTAM Publishing DirectorEmail: TANIFUJI.Mikiko@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Argus Research: Society Pass (Nasdaq: SOPA) – Building a Loyalty-Driven E-Commerce Platform in Southeast Asia ACN Newswire

Argus Research: Society Pass (Nasdaq: SOPA) – Building a Loyalty-Driven E-Commerce Platform in Southeast Asia

SINGAPORE, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Argus Research Company ("Argus Research") issues Equity Research Report on Society Pass Inc. (Nasdaq: SOPA) ("SoPa").Click Here (on Society Pass website) or Here (on Argus Research website) to view the full Argus Research Equity Research Report. https://tinyurl.com/ArgusResearch-SOPA-26AugustSummary Points:- Society Pass Inc. ("SoPa"), founded in 2018 and based in Singapore, operates e-commerce platforms in Southeast Asia ("SEA"). SoPa focuses on the fast-growing markets of Vietnam, Indonesia, Philippines, Singapore, and Thailand, which together account for more than 80% of the Southeast Asian population. SoPa's vertical markets include Lifestyle, Grocery and Food Delivery, Mobile Telecommunications, Loyalty, Travel, and Digital Media. Society Pass completed an initial public offering and began trading on the Nasdaq under the ticker SOPA in November 2021. SOPA shares were added to the Russell 2000 index in December 2021.- SoPa's business model is based upon acquiring smaller e-commerce companies with high growth potential at a relatively low cost and expanding its user base across a robust product and service ecosystem. SoPa plans to integrate these diverse businesses by attracting and retaining customers through a loyalty program called Society Points, which has entered beta testing and is expected to launch broadly in the beginning of 2023. Loyalty program members will be able to redeem points to make purchases directly from Society Pass or from affiliated merchants. They will also receive personalized promotions and discounts based on the company's data capabilities and understanding of consumer shopping behaviour. Argus Research believes that this open-loop loyalty program differentiates Society Pass from other regional competitors.- As of August 2022, SoPa has amassed more than 3.3 million registered consumers and over 205,700 affiliated merchants and brands. Second-quarter 2022 revenues of approximately $500,000 reflect the nascent stage of its platform rollout.- Argus Research has a favourable view of SoPa's target markets given its still limited e-commerce capabilities and strong projected growth. Vietnam, Indonesia, Philippines, Singapore, and Thailand all have young, rapidly-growing populations with a median age of 25-32, compared to an estimated 42 in China, a much more mature market. SEA economies are also growing at a faster-than-average rate. According to the International Monetary Fund, since 2010, SEA has averaged 4.6% GDP growth, compared to 0.7% in Japan, 0.8% in the EU, and 1.7% in the US.- Argus Research forecasts 2022 revenues of $7 million and 2023 revenue of $30 million, primarily driven by Leflair and supported by Pushkart, Handycart, and other recently completed acquisitions. Argus Research expects the broad launch of the Society Points programs to accelerate the revenue growth trajectory, and Argus Research forecasts a revenue run rate of approximately $40 million by the end of 2023 (for entities whose acquisition have already closed).- SoPa's recent market cap near $50 million is close to one-time 2023 year-end revenue run-rate forecast of $40 million, and well below the average multiple of four-to-five times for a basket of comparable e-commerce peers. Argus Research believes the current valuation does not seem to reflect adequately SoPa's growth prospects, driven by acquisitions, the loyalty points program, and continued economic recovery in SEA. Further, Argus Research thinks that the restructuring of Leflair to a separate entity that can eventually support its own public listing can unlock shareholder value for SoPa, with an attractive return on capital, under a holding company model.- To value Society Pass, Argus Research applies a six-times multiple to a year-end 2023 revenue run-rate forecast of $40 million, discounted back one period at 10%. Argus Research then adjusts based on its outlook for $15 million in cash and share count of 30 million at the end of 2022, and arrive at a fair value estimate for SOPA of $8 per share, well above current levels.- In Argus Research's view, a premium to the peer average is warranted, given the early stage of Society Pass' revenue-growth trajectory. Argus Research notes that its revenue assumptions could change significantly, as the company continues its M&A strategy and integrates new companies into its product and service ecosystem.About Society Pass IncAs a digitally-focused loyalty and data marketing ecosystem in Vietnam, Indonesia, Philippines, Singapore and Thailand and with offices located in Angeles, Bangkok, Hanoi, Ho Chi Minh City, Jakarta, Manila, and Singapore, SoPa is an acquisition-focused e-commerce holding company operating 6 interconnected verticals (loyalty, digital media, travel, telecoms, lifestyle, and F&B), which seamlessly connects millions of registered consumers and hundreds of thousands of registered merchants/brands across multiple product and service categories throughout SEA.SoPa's business model focuses on analysing user data through its Society Pass loyalty platform and circulation of its universal loyalty points or Society Points. The SoPa loyalty platform drives customer acquisition and increases customer retention for merchants. Since its inception, SoPa has amassed over 3.3 million registered consumers and over 205,000 registered merchants/brands onto its platform. It has invested 2+ years building proprietary IT architecture to effectively scale and support its consumers, merchants, and acquisitions.Society Pass leverages technology to tailor a more personalised experience for customers in the purchase journey and to transform the entire retail value chain in SEA. SoPa operates Thoughtful Media Group, a Thailand-based, a social commerce-focused, premium digital video multi-platform network; NusaTrip, a leading Indonesia-based Online Travel Agency; Gorilla Networks, a Singapore-based, web3-enabled mobile blockchain network operator; Leflair.com, Vietnam's leading lifestyle e-commerce platform; Pushkart.ph, a popular grocery delivery company in Philippines; Handycart.vn, a leading online restaurant delivery service based in Vietnam; and Mangan, the leading local restaurant delivery service in Philippines. For more information, please check out: http://thesocietypass.com/.Media Contacts:PRecious Communicationssopa@preciouscomms.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Toyota: Six Private Companies Establish “Research Association of Biomass Innovation for Next Generation Automobile Fuels” JCN Newswire

Toyota: Six Private Companies Establish “Research Association of Biomass Innovation for Next Generation Automobile Fuels”

TOKYO, Jul 20, 2022 - (JCN Newswire via SEAPRWire.com) - ENEOS Corporation (ENEOS), Suzuki Motor Corporation (Suzuki), Subaru Corporation (Subaru), Daihatsu Motor Co. Ltd. (Daihatsu), Toyota Motor Corporation (Toyota), and Toyota Tsusho Corporation (Toyota Tsusho) established the Research Association of Biomass Innovation for Next Generation Automobile Fuels (Research Association) on July 1, 2022, to study ways to optimize the process of producing fuel.It is crucial to provide diverse energy options to meet the needs of many different regions and customers in order to achieve carbon neutrality. Hydrogen and synthetic fuels based on electricity from renewable energy sources, as well as bioethanol fuel able to reduce CO2 emissions through photosynthesis in plants are promising options, and their effectiveness has been confirmed by the Intergovernmental Panel on Climate Change (IPCC). However, it is essential to clarify the issues and search for a solution regarding CO2 emission reduction and social implementation throughout the manufacturing process, in addition to raw material procurement for any of these fuels.This Research Association promotes technological research on the use of biomass, as well as the efficient production of bioethanol fuel for automobiles through the optimized circulation of hydrogen, oxygen, and CO2 during production to achieve a carbon-neutral society. Specific research areas are as follows.1. Research on Efficient Ethanol Production SystemsWith the aim of improving production technology for second-generation bioethanol fuel that does not compete with food, the Research Association will design, install, and operate production facilities, identify issues with production, research solutions and study ways to improve the efficiency of production systems.2. Research on Byproduct Oxygen, CO2 Capture, and UtilizationThe Research Association will study how to use the high concentration of oxygen generated as a byproduct during hydrogen production as well as the CO2 generated during bioethanol fuel production.3. Research on the Efficient Operation of the Overall System, Including Fuel UtilizationThe Research Association will investigate the issues involved with using bioethanol fuel obtained in (1) to automobiles and other vehicles and explore solutions. It will also study model formulas that can make predictions of both raw material cultivation production volumes and fuel production volumes.4. Research on Efficient Raw Material Crop Cultivation MethodsThe Research Organization will develop a system that proposes optimal cultivation methods for maximizing yield and optimizing crop components to secure raw materials for bioethanol fuels. It will aim to improve the accuracy of crop yield productions through soil composition surveys and other methods. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Receives “Best Biologics CRO Award 2022” at Korea Bioprocessing Excellence Awards 2022 ACN Newswire

Novotech Receives “Best Biologics CRO Award 2022” at Korea Bioprocessing Excellence Awards 2022

SEOUL, S.KOREA, Jun 29, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, and the 3rd BioLogistics World Korea conferences (29th - 30th June 2022) which attract more than 300 representatives from Korea's top biopharmas, vaccine manufacturers, and biologics companies.Novotech Country Managing Director Sanghee Kim said the Korea team was extremely pleased to receive this award in recognition of the clinical excellence provided to clients in the biologics sector.Novotech Vice President Global Head Clinical Services Yooni Kim also said: "Novotech's Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions."Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, New Zealand, South Korea, Greater China, Southeast Asia, India, South Africa and the US.Novotech CEO Dr. John Moller said: "The focus on Asia-Pacific for biotech clinical research over the past five years makes the region the fastest-growing clinical trial destination with China being the leading location for new trials followed by the US. Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms have accelerated approval processes. The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs. Clients will receive a seamless service, with a unified approach to systems and SOPs," Moller said. About Novotech Health HoldingsNovotech Health Holdings Pte. Ltd. ("Novotech") is the leading Asia-Pacific and US biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More